Zilovertamab vedotin, an antibody–drug conjugate (ADC) targeting ROR1, demonstrated response rates of 47% and 60% in mantle cell and diffuse large B-cell lymphomas, respectively [28]. The gene discussed is ROR1; the disease is diffuse large B-cell lymphoma.